SARS-COV-2 rbd nanoparticle
SARS-COV-2 rbd nanoparticle has been studied in 1 paper since 2021: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Sep 9, 2021: “An adjuvanted SARS-CoV-2 RBD nanoparticle elicits neutralizing antibodies and fully protective immunity in aged mice”.
1 paper studies it2 findingsUpdated
See all 1 papers on SARS-COV-2 rbd nanoparticle
At a glance
The findings reach mice, none yet in people. 1 lab in 1 country.
None of its findings points the other way.
- 1 lab in 1 country
- Funders: Daiichi Sankyo Europe and 8 more
- 2 of 2 findings with company ties
- Animals1
What did studies of SARS-COV-2 rbd nanoparticle find?
2Studies of SARS-COV-2 rbd nanoparticle measured 2 outcomes: cross-neutralizing antibodies and immune response.
Cross-neutralizing antibodies
upin mice1
1 study
Cross-neutralizing antibodies
upin mice1
SARS-COV-2 rbd nanoparticle increases cross-neutralizing antibodies in mice (compared to other oil-in-water emulsions or AS01B).
“induced the highest levels of cross-neutralizing antibodies compared to other oil-in-water emulsions or AS01B”
Animalscompared to other oil-in-water emulsions or AS01B
bioRxiv (Cold Spring Harbor Laboratory)Preprint
Immune response
upin mice1
1 study
Immune response
upin mice1
SARS-COV-2 rbd nanoparticle induces immune response in mice.
“SARS-CoV-2 receptorbinding domain (RBD) displayed as a protein nanoparticle (RBD-NP) was a highly effective antigen”
Animals
bioRxiv (Cold Spring Harbor Laboratory)Preprint